Personalis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 01:39 am IST
Share
Personalis, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 16.7 million compared to USD 18.24 million a year ago. Net loss was USD 23.96 million compared to USD 27.55 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.6 a year ago. Diluted loss per share from continuing operations was USD 0.5 compared to USD 0.6 a year ago.
For the six months, sales was USD 35.56 million compared to USD 33.47 million a year ago. Net loss was USD 52.61 million compared to USD 55.76 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.23 a year ago. Diluted loss per share from continuing operations was USD 1.11 compared to USD 1.23 a year ago.
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
PERSONALIS, INC. 
